🟢 Moleculin Biotech is trading 12.5% up in pre-market after completing Part A dosing in AML trial

Moleculin Biotech is trading at $8.89, up +12.53%, with the trial dosing milestone a plausible catalyst for the pre-market gain.

• The October 30 announcement said dosing was complete in Part A of the pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory AML.
• Full data are expected in Q1 2027; the announcement did not report efficacy results. Major U.S. indexes were up more than 0.5%.